Curing Allergy

To NASDAQ OMX Copenhagen A/S

Company release No. 19/2012

Six-month interim report (Q2) 2012 (unaudited)

Performance for the period

(Comparative figures for the same period of last year are shown in brackets / sales growth is measured in local currencies)

Revenue and operating result in Q2 were as expected and in line with the full year outlook. It should be noted that revenue and earnings in H1 2011 were particularly affected by an extraordinarily high level of income of DKK 184 million from partners (DKK 60 million in H1 2012) and revenue from an inlicensed adrenaline pen which is currently being replaced by sales of ALK's own brand Jext®.

- Revenue in H1 ended at DKK 1,122 million (1,258).
- Vaccine sales grew by 3%. AIT sales grew by 19%.
- Growth was especially driven by positive developments in SLIT and AIT sales in France and by SCIT and AIT sales in Central and Northern Europe, respectively.
- Operating profit (EBITDA) was DKK 79 million (285).
- At the end of the warranty period, ALK has reversed a provision and adjusted a debt obligation of DKK 155 million in total which were part of the representations and warranties given to the buyer of the ingredients business, Chr. Hansen A/S, in 2005. The gain is presented separately in the income statement as net profit, past discontinued operations.
- Net profit was DKK 168 million (140).
- Free cash flow was an outflow of DKK 166 million (an inflow of 241), and cash and cash equivalents stood at DKK 492 million.

ALK's business activities have continued to progress:

- ALK's Japanese partner, Torii, has advanced the clinical development programme for MITIZAX® and initiated two parallel Phase II/III trials in Japan in July, which released a milestone payment to ALK.
- ALK's North American partner, Merck (known as MSD outside the USA and Canada), has disclosed that the company will initiate a Phase IIb clinical trial for HDM AIT (known as MITIZAX® in Europe).
- Additionally, Merck has informed ALK of the results from a recently completed safety trial with ragweed AIT. The results confirm Merck's plans for filing of a New Drug Application with the U.S. Food and Drug Administration in 2013.

Unchanged outlook for 2012

For the 2012 financial year, ALK expects growth in vaccines sales of 3-5%, total revenue of up to DKK 2.4 billion and a record-high activity level within R&D. ALK still expects operating profit before depreciation and amortisation (EBITDA) to exceed DKK 300 million. Compared to H1, the last six months of 2012 is expected to show continued growth in vaccine sales, which will be supported by a new SLIT product, and higher adrenaline sales as well as higher partner revenues. H2 is likely to show capacity costs on level with H1.

Hørsholm, 16 August 2012

ALK-Abelló A/S

Contact:
Jens Bager, President and CEO, tel. +45 4574 7576

ALK is holding a conference call for analysts and investors today at 2.00 p.m. (CET) at which Jens Bager, President and CEO, and Flemming Pedersen, CFO, will review the results. Participants in the conference call are kindly requested to call in before 1.55 p.m. (CET). Danish participants should call in on tel. +45 7014 0453 and international participants should call in on tel. +44 20 7750 9950. The conference call will also be webcast on our website, www.alk-abello.com/investor, where the related presentation will be available shortly before the conference call begins.

FINANCIAL HIGHLIGHTS AND KEY RATIOS FOR THE ALK GROUP (unaudited)

Amounts in DKKm	H1 2012	H1 2011	Full year 2011
Income statement			
Revenue	**1,122**	1,258	2,348
Operating profit (EBIT)	**17**	235	299
Net financial items	**4**	(5)	22
Profit before tax (EBT)	**21**	230	321
Net profit, continuing operations	**13**	140	200
Net profit, past discontinued operations	**155**	-	-
Net profit	**168**	140	200
Operating profit before depreciation and amortisation (EBITDA)	**79**	285	406
Average number of employees	**1,804**	1,710	1,724
Balance sheet			
Total assets	**3,207**	2,945	3,354
Invested capital	**2,002**	1,605	1,644
Equity	**2,278**	2,090	2,167
Cash flow and investments			
Depreciation, amortisation and impairment	**62**	50	107
Cash flow from operating activities	**(71)**	287	431
Cash flow from investing activities	**(95)**	(46)	(160)
- of which investment in tangible assets	**(84)**	(35)	(118)
Free cash flow	**(166)**	241	271
Information on shares			
Share capital	**101**	101	101
Shares in thousands of DKK 10 each	**10,128**	10,128	10,128
Share price, end of period – DKK	**348**	314	321
Net asset value per share – DKK	**225**	206	215
Key figures			
Gross margin – %	**71**	74	74
EBITDA margin – %	**7**	23	17
Earnings per share (EPS) – DKK	**17.17**	14.14	20.21
Earnings per share (EPS), continuing operations – DKK	**1.33**	14.14	20.21
Earnings per share (DEPS), diluted – DKK	**17.10**	14.14	20.21
Earnings per share (DEPS), diluted, continuing operations – DKK	**1.32**	14.14	20.21
Cash flow per share (CFPS) – DKK	**(7.26)**	28.99	43.49
Share price/Net asset value	**1.5**	1.5	1.5

Definitions: see last page

ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk-abello.com
Tel +45 4574 7576 – Fax +45 4574 8607 – CVR No 63 71 79 16

INCOME STATEMENT

Q2 2011	%	Q2 2012	%	Amounts in DKKm	H1 2012	%	H1 2011	%
515	100	**515**	100	**Revenue**	**1,122**	100	1,258	100
145	28	**163**	32	Cost of sales	**325**	29	321	26
370	72	**352**	68	**Gross profit**	**797**	71	937	74
105	20	**136**	26	Research and development expenses	**263**	23	211	17
247	48	**270**	52	Sales, marketing and administrative expenses	**517**	46	493	39
-	-	**-**	-	Other operating income and expenses	**-**	-	2	-
18	3	**(54)**	(10)	**Operating profit/(loss) (EBIT)**	**17**	2	235	19
3	1	**8**	2	Financial income	**14**	1	4	-
(1)	(0)	**(1)**	(0)	Financial expenses	**10**	1	9	1
22	4	**(45)**	(9)	**Profit/(loss) before tax (EBT)**	**21**	2	230	18
9	2	**(18)**	(3)	Tax on profit	**8**	1	90	7
13	3	**(27)**	(5)	**Net profit/(loss), continuing operations**	**13**	1	140	11
-	-	**155**	30	Net profit, past discontinued operations	**155**	14	-	-
13	3	**128**	25	**Net profit**	**168**	15	140	11
43	8	**(23)**	(4)	**Operating profit/(loss) before depreciation and amortisation (EBITDA)**	**79**	7	285	23

FINANCIAL REVIEW

(*Growth rates for revenue are stated as growth in local currencies, unless otherwise indicated*)

Total **revenue** consists of sales of allergy immunotherapy products and other products as well as other revenue, including license income from partners.

Revenue in the second quarter was DKK 515 million (515), with total net sales growth of 3%. As in the first quarter, growth was driven in particular by positive developments in SLIT and AIT sales in France and by SCIT and AIT sales in Central and Northern Europe, respectively.

Revenue in H1 was DKK 1,122 million (1,258). Growth in vaccine sales in H1 was 3% and in line with the financial outlook of 3-5% for the full year. When comparing revenue in H1 2012 with the same period of last year it should be noted that revenue in 2011 was affected by an extraordinarily high level of partner income and by discontinued sales of an inlicensed adrenaline pen. Exchange rates affected reported growth positively by approximately 1 p.p.



Revenue – product lines

In the first half-year, sales of SCIT increased 2% to DKK 481 million (465). Performance has been positive in all European regions although the development in Spain and Italy, in particular, continues to be affected by a difficult macro-economic environment. Sales of injection based allergy immunotherapy products accounted for 43% (37) of the company's total revenue.

Sales of SLIT declined by 1% to DKK 375 million (380) primarily as a consequence of the phasing-out of non-registered products in the Netherlands, ALK's second-largest SLIT market. The phasing-out of products was as expected. On the positive side, the development in France, the largest SLIT market, continues to be very encouraging. SLIT products accounted for 33% (30) of the company's total revenue.

Sales of AIT, tablet based products (GRAZAX®), increased by 19% to DKK 116 million (97). The underlying volume growth was more than 25%. In the second quarter, sales growth accelerated due to positive developments in France and the Nordic countries. Tablet sales accounted for 10% (8) of the company's total revenue.

Sales of other products (adrenaline pens, diagnostics, etc.) declined 34% to DKK 90 million (132). The decrease was solely caused by discontinued sales of an inlicensed adrenaline product. Sales of that product are now being replaced by sales of ALK's own product, Jext®, which was launched in Europe towards the end of last year. The reception of Jext® by the markets continues to be promising and ALK believes it will have fully re-established its adrenaline sales within the next few years. In addition, sales of diagnostic products developed positively, in particular in North America. Sales of other products accounted for 8% (10) of the company's total revenue.



Revenue – markets

In the Northern European region, sales declined by 23% to DKK 197 million (254). The positive performance of SCIT and AIT sales was offset by the discontinued sales of the inlicensed adrenaline pen and by an expected decline of sales in the Netherlands of almost DKK 20 million, equivalent to a negative impact of approximately 2 p.p. on growth in total vaccine sales.

In Central Europe, sales were unchanged at DKK 352 million (352). A strong performance of SCIT sales in Germany was offset by a general market and regulatory pressure on SLIT products.

In the Southern European region, sales grew by 10% to DKK 370 million DKK (336). The growth was due to a satisfactory performance of SLIT and AIT sales in France. In Spain and Italy, market conditions are still challenging as a consequence of the macroeconomic environment.

Sales in other markets were unchanged at DKK 143 million (132). A positive development in North American sales of diagnostic products was offset by quarterly fluctuations in Chinese sales.

Revenue – other revenue

Other revenue for the first six months totalled DKK 60 million (184), mainly relating to revenues from ALK's partners in Japan and North America. Other revenue accounted for 5% (15) of the company's total revenue.

On entering into the partnership with Torii in 2011, ALK received an up-front payment of DKK 224 million of which DKK 75 million is expected to be

ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk-abello.com
Tel +45 4574 7576 – Fax +45 4574 8607 – CVR No 63 71 79 16

recognised in 2012, to be split evenly over the quarters.

Furthermore, ALK has recognised income relating to development activities carried out by ALK for Merck and Torii.

Costs and earnings
In the first half-year, **cost of sales** totalled DKK 325 million (321) and gross profit decreased to DKK 797 million (937). The reported gross margin fell to 71% (74). Disregarding other revenue from partners, the underlying gross margin decreased slightly due to increasing activity level and depreciations in the product supply area.

Total **capacity costs** increased by 11% to DKK 780 million (704). The increase was due to ALK's decision in late 2011 to accelerate its research and development activities with a view to securing a rapid development of a broader AIT product portfolio. Research and development expenses consequently rose 25% whereas sales, marketing and administration expenses increased slightly primarily due to the recent European launch of a new improved SLIT product and the continued roll-out of the new adrenaline pen. Exchange rates have affected capacity costs negatively.

Operating profit before depreciation and amortisation (EBITDA) ended at DKK 79 million (285). Disregarding the extraordinarily high level of partner revenues last year, EBITDA mainly declined as a consequence of increasing research and development expenses. Exchange rates have not significantly affected operating profit.

Net financials were a profit of DKK 4 million (a loss of 5), which was primarily due to unrealised exchange gains related to USD.

Tax on the profit for the period totalled DKK 8 million (90), corresponding to an effective tax rate of 39% (39).

In connection with the divestment of the ingredients business, Chr. Hansen A/S, in 2005, ALK assumed the usual representations and warranties towards the buyer, and a provision of DKK 140 million to cover specific risks was recognised. Furthermore, specific debt obligations related to the sale were recognised.

On expiry of the warranty period at the end of July 2012, management assessed the company's liabilities towards the buyer, which resulted in a reversal of the provision of DKK 140 million and an adjustment of debt obligations by DKK 15 million. The total amount of DKK 155 million has been recognised as an adjustment of the original gain on the divestment of Chr. Hansen A/S and is presented separately in the income statement as net profit, past discontinued operations. The recognition has not affected the company's cash flows or tax. The **net profit** for the period was thus DKK 168 million (140).

Cash flow from operating activities was an outflow of DKK 71 million (an inflow of 287) and was negatively affected by changes in short-term payables as a consequence of changes in deferred income and investments made at the end of 2011. Cash flow from investing activities was an outflow of DKK 95 million (46) relating to amongst other things the expansion of production facilities in France. Free cash flow for the period was an outflow of DKK 166 million (an inflow of 241). Cash flow from financing activities was an outflow of DKK 91 million (58) relating to the announced share buy-back programme and ordinary dividends. At the end of June, cash and cash equivalents totalled DKK 492 million, compared to DKK 754 million at the end of 2011.

At the end of June, ALK's total holding of **treasury shares** was 378,223 shares, corresponding to 3.7% of the total number of issued shares of 10,128,360. The market value of the treasury shares was approximately DKK 130 million.

Equity totalled DKK 2,278 million (2,090) at the end of the period, and the equity ratio was thus 71% (71).

Outlook for the 2012 financial year
For the 2012 financial year, ALK expects continued growth in revenue and robust earnings.

ALK still expects growth of 3-5% in vaccine sales measured in local currencies. ALK expects a

ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk-abello.com
Tel +45 4574 7576 – Fax +45 4574 8607 – CVR No 63 71 79 16

significant contribution to revenue from its partnerships with Merck and Torii, although at a lower level than in 2011 when revenues from partners were extraordinarily high. Total revenue of up to DKK 2.4 billion is still expected for 2012.

ALK recently decided to accelerate its AIT development programme with a view to securing a rapid development of a broader product portfolio to increase the overall commercial potential of AIT. This acceleration will mean increasing research and development expenses in 2012 and 2013, in particular.

Operating profit (EBITDA) for 2012 is still expected to exceed DKK 300 million. This is lower than in 2011 and is mainly due to the high level of research and development investments and anticipated lower revenues from partners.

Compared to H1, the last six months of 2012 is expected to show continued growth in vaccine sales, which will be supported by a new SLIT product, and higher adrenaline sales as well as higher partner revenues. H2 is likely to show capacity costs on level with H1.

The outlook is based on the current exchange rates. The company's revenue and earnings are only to a minor extent exposed to foreign exchange fluctuations.

OPERATING REVIEW

Partnerships

An essential part of ALK's strategy is to ensure global access to allergy immunotherapy through partnerships with other pharmaceutical companies. At present, ALK has two strategic partnerships on commercialisation of AIT covering the world's two largest pharmaceutical markets, the USA and Japan.

ALK has close and committed partnerships with both Merck and Torii and they continue to progress satisfactorily.

North America: Partnership with Merck

The partnership with Merck covers the development, registration and commercialisation of a portfolio of allergy immunotherapy tablets (AITs) against grass pollen, ragweed and house dust mite (HDM) allergy in the USA, Canada and Mexico.

Merck has recently disclosed on www.clinicaltrials.gov that the company will initiate a Phase IIb clinical trial for HDM AIT (known as MITIZAX® in Europe). The purpose of this trial is to evaluate the dose-related effectiveness, the safety and the tolerability of HDM AIT compared to placebo in the treatment of HDM-induced allergic rhinitis/rhinoconjunctivitis in adults. The trial is expected to enrol an estimated 120 patients and to complete in 2013.

Merck has successfully completed two Phase III clinical trials with ragweed AIT. In late 2011, Merck initiated an additional safety trial of approximately 900 patients, which has now been completed. Merck has informed ALK of the trial results, which confirm Merck's timeline for filing of a New Drug Application (NDA) for ragweed AIT with the U.S. Food and Drug Administration (FDA) in 2013.

In 2011, Merck initiated a North American Phase III clinical trial to evaluate the efficacy of grass AIT (marketed under the name of GRAZAX® in Europe) versus placebo in the treatment of grass pollen induced allergic rhinoconjunctivitis. The trial includes approximately 1,500 patients and is progressing as planned. The trial is scheduled to complete in 2012.

Merck plans to file a NDA for grass AIT with the FDA in 2013.

In 2011, Merck submitted a registration application for grass AIT to Health Canada, and Merck recently received a Notice of Deficiency. Merck is discussing next steps with the health authorities, including new data that are expected to be available later in 2012, which may address Health Canada's comments.

ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk-abello.com
Tel +45 4574 7576 – Fax +45 4574 8607 – CVR No 63 71 79 16

Japan: Partnership with Torii
The partnership with Torii covers the development, registration and commercialisation of, among other products, MITIZAX® in Japan. The agreement also covers ALK's existing injection based allergy immunotherapy and diagnostic products against house dust mite allergy as well as an agreement on joint research and development of an AIT against Japanese cedar allergy.

Torii has recently advanced the clinical development programme for MITIZAX® by initiating two parallel Phase II/III trials in Japan.

The two trials will include approximately 1,800 subjects and will investigate safety and efficacy of MITIZAX® in the treatment of house dust mite induced allergic rhinitis and asthma in a Japanese population. Initiation of patient dosing in the Phase II/III trials in Japan entitles ALK to a milestone payment from Torii which is expected to be recognised in Q3 2012.

In Europe, ALK is currently conducting two similar clinical Phase III trials which will complete in 2013.

New member of Board of Management
On 1 August 2012, Søren Daniel Niegel (41 years) joined ALK as Executive Vice President (International Sales & Marketing) and member of the Board of Management.

Søren Daniel Niegel holds a M.Sc. in Economics and Business Administration from Copenhagen Business School. He joins ALK from a position as Vice President Strategic Operations Europe at Novo Nordisk. From his many different positions at Novo Nordisk in Denmark, the Netherlands, France and Switzerland, Søren Daniel Niegel has gained significant management and business experience.

Risk factors
This interim report contains forward-looking statements, including forecasts of future revenue and operating profit as well as expected business-related events. Such statements are subject to risks and uncertainties as various factors, some of which are beyond the control of the ALK Group, may cause actual results and performance to differ materially from the forecasts made in this interim report. Without being exhaustive, such factors include, e.g. general economic and business conditions, including legal issues, uncertainty relating to pricing, reimbursement rules, fluctuations in currencies and demand, changes in competitive factors and reliance on suppliers, but also factors such as side effects from the use of the company's existing and future products since allergy immunotherapy may be associated with allergic reactions of differing extent, duration and severity.

2012 Financial calendar

Silent period	15 October 2012
Nine-month interim report (Q3) 2012	12 November 2012

ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk-abello.com
Tel +45 4574 7576 – Fax +45 4574 8607 – CVR No 63 71 79 16

STATEMENT BY THE MANAGEMENT

The Board of Directors and Board of Management today considered and approved the interim report of ALK-Abelló A/S for the period 1 January – 30 June 2012.

The interim report has been prepared in accordance with IAS 34 “Interim financial reporting” as adopted by the EU and additional Danish disclosure requirements for the interim reports of listed companies. As in previous years, the interim report has not been subject to audit or review.

In our opinion, the interim report gives a true and fair view of the Group’s assets, equity and liabilities, financial position, results of operations and cash flows for the period 1 January – 30 June 2012. Moreover, in our opinion, the interim report gives a true and fair view of developments in the Group’s activities and financial position and describes significant risk and uncertainty factors that may affect the Group.

Hørsholm, 16 August 2012

Board of Management

Jens Bager (President and CEO)	Henrik Jacobi	Flemming Steen Jensen
Søren Daniel Niegel	Flemming Pedersen	

Board of Directors

Steen Riisgaard (Chairman)	Christian Dyvig (Vice Chairman)	Lars Holmqvist
Jacob Kastrup	Thorleif Krarup	Anders Gersel Pedersen
Dorthe Seitzberg	Katja Barnkob Thalund	Jes Østergaard

INCOME STATEMENT (unaudited)

ALK Group			ALK Group	
Q2 2011	**Q2 2012**	Amounts in DKKm	**H1 2012**	**H1 2011**
515	**515**	**Revenue**	**1,122**	1,258
145	**163**	Cost of sales	**325**	321
370	**352**	**Gross profit**	**797**	937
105	**136**	Research and development expenses	**263**	211
194	**216**	Sales and marketing expenses	**413**	391
53	**54**	Administrative expenses	**104**	102
-	**-**	Other operating income	**-**	2
18	**(54)**	**Operating profit/(loss) (EBIT)**	**17**	235
3	**8**	Financial income	**14**	4
(1)	**(1)**	Financial expenses	**10**	9
22	**(45)**	**Profit/(loss) before tax (EBT)**	**21**	230
9	**(18)**	Tax on profit	**8**	90
13	**(27)**	**Net profit/(loss), continuing operations**	**13**	140
-	**155**	Net profit, past discontinued operations	**155**	-
13	**128**	**Net profit**	**168**	140
1.31	**13.11**	Earnings per share (EPS) – DKK	**17.17**	14.14
1.31	**(2.77)**	Earnings per share (EPS), continuing operations – DKK	**1.33**	14.14
1.31	**13.04**	Earnings per share (DEPS), diluted – DKK	**17.10**	14.14
1.31	**(2.77)**	Earnings per share (DEPS), diluted, continuing operations – DKK	**1.32**	14.14

STATEMENT OF COMPREHENSIVE INCOME (unaudited)

ALK Group			ALK Group	
Q2 2011	**Q2 2012**	Amounts in DKKm	**H1 2012**	**H1 2011**
13	**128**	**Net profit for the period**	**168**	140
		Other comprehensive income		
(5)	**20**	Foreign currency translation adjustment of foreign subsidiaries	**11**	(26)
-	**-**	Net fair value adjustment of financial assets available for sale	**24**	-
-	**(2)**	Tax related to other comprehensive income	**(7)**	3
(5)	**18**	**Other comprehensive income**	**28**	(23)
8	**146**	**Total comprehensive income**	**196**	117

ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk-abello.com
Tel +45 4574 7576 – Fax +45 4574 8607 – CVR No 63 71 79 16

CASH FLOW STATEMENT (unaudited)

	ALK Group	
Amounts in DKKm	**H1 2012**	**H1 2011**
Net profit	**168**	140
Adjustments:		
Change in provisions and payables from past discontinued operations	**(155)**	-
Tax on profit	**8**	90
Financial income and expenses	**(4)**	5
Share-based payments	**5**	5
Depreciation, amortisation and impairment	**62**	50
Change in provisions	**3**	(1)
Net financial items, paid	**10**	2
Income taxes, paid	**(91)**	(76)
Cash flow before change in working capital	**6**	215
Change in inventories	**6**	25
Change in receivables	**(11)**	13
Change in short-term payables	**(72)**	34
Cash flow from operating activities	**(71)**	287
Additions, intangible assets	**(11)**	(11)
Additions, tangible assets	**(84)**	(35)
Cash flow from investing activities	**(95)**	(46)
Free cash flow	**(166)**	241
Dividend paid to shareholders of the parent	**(49)**	(50)
Purchase of treasury shares	**(41)**	-
Change in financial liabilities	**(1)**	(8)
Cash flow from financing activities	**(91)**	(58)
Cash flow from past discontinued operations	**-**	-
Net cash flow	**(257)**	183
Cash and cash equivalents at 1 January	**754**	250
Unrealised gain/(loss) on foreign currency and financial assets carried as cash and cash equivalents	**(5)**	-
Net cash flow	**(257)**	183
Cash and cash equivalents at 30 June	**492**	433

The cash flow statement has been adjusted to the effect that exchange rate adjustments in foreign subsidiaries are not included in the statement. As a result, the individual figures in the cash flow statement cannot be reconciled directly to the income statement and balance sheet.

BALANCE SHEET (unaudited)

Assets	ALK Group		
Amounts in DKKm	**30 June 2012**	**31 Dec. 2011**	**30 June 2011**
Non-current assets			
Intangible assets			
Goodwill	**408**	408	406
Other intangible assets	**209**	211	197
	617	619	603
Tangible assets			
Land and buildings	**661**	561	549
Plant and machinery	**271**	176	165
Other fixtures and equipment	**63**	62	65
Property, plant and equipment in progress	**286**	437	391
	1,281	1,236	1,170
Other non-current assets			
Securities and receivables	**60**	35	28
Deferred tax assets	**57**	68	63
	117	103	91
Total non-current assets	**2,015**	1,958	1,864
Current assets			
Inventories	**283**	291	279
Trade receivables	**241**	254	214
Receivables from affiliates	**-**	-	27
Income tax receivables	**86**	30	44
Other receivables	**57**	31	52
Prepayments	**33**	36	32
Cash and cash equivalents	**492**	754	433
Total current assets	**1,192**	1,396	1,081
Total assets	**3,207**	3,354	2,945

ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk-abello.com
Tel +45 4574 7576 – Fax +45 4574 8607 – CVR No 63 71 79 16

BALANCE SHEET (unaudited)

Equity and liabilities	ALK Group		
Amounts in DKKm	**30 June 2012**	**31 Dec. 2011**	**30 June 2011**
Equity			
Share capital	**101**	101	101
Currency translation adjustment	**1**	(9)	(33)
Retained earnings	**2,176**	2,075	2,022
Total equity	**2,278**	2,167	2,090
Liabilities			
Non-current liabilities			
Mortgage debt	**25**	25	26
Bank loans and financial loans	**304**	305	9
Pensions and similar liabilities	**97**	93	87
Other provisions	**1**	142	146
Deferred tax liabilities	**26**	21	26
	453	586	294
Current liabilities			
Mortgage debt	**1**	1	1
Bank loans and financial loans	**3**	3	3
Trade payables	**90**	147	83
Income taxes	**25**	61	82
Other payables	**320**	315	308
Deferred income	**37**	74	84
	476	601	561
Total liabilities	**929**	1,187	855
Total equity and liabilities	**3,207**	3,354	2,945

ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk-abello.com
Tel +45 4574 7576 – Fax +45 4574 8607 – CVR No 63 71 79 16

EQUITY (unaudited)

ALK Group

Amounts in DKKm	Share capital	Other reserves: Foreign currency translation adjustment	Retained earnings	Total equity
Equity at 1 January 2012	**101**	**(9)**	**2,075**	**2,167**
Net profit	-	-	168	168
Foreign currency translation adjustment of foreign subsidiaries	-	11	-	11
Net fair value adjustment of financial assets available for sale	-	-	24	24
Tax related to other comprehensive income	-	(1)	(6)	(7)
Other comprehensive income	**-**	**10**	**18**	**28**
Total comprehensive income	**-**	**10**	**186**	**196**
Share-based payments	-	-	5	5
Purchase of treasury shares	-	-	(41)	(41)
Dividend paid	-	-	(51)	(51)
Dividends on treasury shares			2	2
Other transactions	**-**	**-**	**(85)**	**(85)**
Equity at 30 June 2012	**101**	**1**	**2,176**	**2,278**
Equity at 1 January 2011	**101**	**(10)**	**1,927**	**2,018**
Net profit	-	-	140	140
Foreign currency translation adjustment of foreign subsidiaries	-	(26)	-	(26)
Tax related to other comprehensive income	-	3	-	3
Other comprehensive income	**-**	**(23)**	**-**	**(23)**
Total comprehensive income	**-**	**(23)**	**140**	**117**
Share-based payments	-	-	5	5
Dividend paid	-	-	(50)	(50)
Other transactions	**-**	**-**	**(45)**	**(45)**
Equity at 30 June 2011	**101**	**(33)**	**2,022**	**2,090**

ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk-abello.com
Tel +45 4574 7576 – Fax +45 4574 8607 – CVR No 63 71 79 16

NOTES (unaudited)

1 ACCOUNTING POLICIES

The interim report for the period 1 January to 30 June 2012 is presented in accordance with IAS 34 "Interim financial reporting" as adopted by the EU and additional Danish disclosure requirements for interim reports of listed companies. The additional Danish disclosure requirements are defined in the Danish Executive Order on Interim Reports issued under the Danish Financial Statements Act.

The accounting policies are unchanged compared to the Annual Report 2011. Please see this report for a more detailed description of the Group's accounting policies.

2 REVENUE

ALK Group				ALK Group	
Q2 2011	Q2 2012	Note	Amounts in DKKm	H1 2012	H1 2011
			Net sales by product line		
204	**218**		SCIT	**481**	465
175	**163**		SLIT	**375**	380
46	**59**		AIT	**116**	97
425	**440**		**Total vaccines**	**972**	942
40	**46**		Other products	**90**	132
465	**486**		**Total net sales**	**1,062**	1,074
50	**29**		Other revenue	**60**	184
515	**515**		**Total revenue**	**1,122**	1,258
			Revenue by market		
104	**98**		Northern Europe	**197**	254
153	**155**		Central Europe	**352**	352
142	**159**		Southern Europe	**370**	336
66	**74**		Other markets	**143**	132
465	**486**		**Total net sales**	**1,062**	1,074
50	**29**		Other revenue	**60**	184
515	**515**		**Total revenue**	**1,122**	1,258

Q2 2012			H1 2012	
Growth	**Growth local currencies**		**Growth local currencies**	**Growth**
7%	**4%**	SCIT	**2%**	**3%**
-7%	**-7%**	SLIT	**-1%**	**-1%**
28%	**27%**	AIT	**19%**	**20%**
4%	**2%**	**Total vaccines**	**3%**	**3%**
15%	**8%**	Other products	**-34%**	**-32%**
5%	**3%**	**Total net sales**	**-2%**	**-1%**
-42%	**-47%**	Other revenue	**-68%**	**-67%**
0%	**-2%**	**Total revenue**	**-12%**	**-11%**
-6%	**-7%**	Northern Europe	**-23%**	**-22%**
1%	**2%**	Central Europe	**0%**	**0%**
12%	**12%**	Southern Europe	**10%**	**10%**
12%	**0%**	Other markets	**1%**	**8%**
5%	**3%**	**Total net sales**	**-2%**	**-1%**
-42%	**-47%**	Other revenue	**-68%**	**-67%**
0%	**-2%**	**Total revenue**	**-12%**	**-11%**

ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk-abello.com
Tel +45 4574 7576 – Fax +45 4574 8607 – CVR No 63 71 79 16

NOTES (unaudited)

3 DISCONTINUED OPERATIONS

In connection with the divestment of the ingredients business, Chr. Hansen A/S, in 2005, ALK-Abelló A/S assumed the usual representations and warranties towards the buyer, and a provision of DKK 140 million was recognised to cover specific risks. Furthermore, specific debt obligations related to the sale were recognised.

On expiry of the warranty period at the end of July 2012, the management assessed the company's liabilities towards the buyer, which resulted in a reversal of the provision of DKK 140 million and an adjustment of debt obligations by DKK 15 million. The total amount of DKK 155 million has been recognised as an adjustment of the original gain on the divestment of Chr. Hansen A/S and is presented separately in the income statement as Net profit, past discontinued operations. The recognition has not affected the company's cash flows or tax.

4 KEY CURRENCIES AND CURRENCY SENSITIVITY

Average exchange rates

	H1 2012	H1 2011
USD	**5.72**	5.29
GBP	**9.03**	8.53

Sensitivity in the event of a 10% increase in exchange rates (full year effect)

Amounts in DKKm	Net sales	EBITDA
USD	**approx. + 20**	**approx. 0**
GBP	**approx. + 5**	**approx. 0**

The sensitivities are estimated on the basis of current exchange rates.

ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk-abello.com
Tel +45 4574 7576 – Fax +45 4574 8607 – CVR No 63 71 79 16

DEFINITIONS

Invested capital	*Intangible assets, tangible assets, inventories and current receivables reduced by liabilities except for mortgage debt, bank loans and financial loans*
Gross margin – %	*Gross profit x 100 / Revenue*
EBITDA margin – %	*Operating profit before depreciation and amortisation x 100 / Revenue*
Net asset value per share	*Equity at end of period / Number of shares at end of period*
Earnings per share (EPS)	*Net profit/(loss) for the period / Average number of outstanding shares*
Earnings per share (DEPS), diluted	*Net profit/(loss) for the period / Diluted average number of outstanding shares*
Cash flow per share (CFPS)	*Cash flow from operating activities / Average number of outstanding shares*
Markets	*Geographical markets (based on customer location):* *- Northern Europe comprises the Nordic region, the UK and the Netherlands* *- Central Europe comprises Germany, Austria, Switzerland, Poland and minor selected markets in Eastern Europe* *- Southern Europe comprises Spain, Italy, France, Greece, Portugal and minor markets in Southern Europe* *- Other markets comprise the USA, Canada, China and rest of world*

Key figures are calculated in accordance with "Recommendations and Ratios 2010" issued by the Danish Society of Financial Analysts.

ALK-Abelló A/S – Bøge Allé 6-8 – DK-2970 Hørsholm – Denmark – www.alk-abello.com
Tel +45 4574 7576 – Fax +45 4574 8607 – CVR No 63 71 79 16